MediWound Ltd. (NASDAQ: MDWD) stock fell by 1.23% at last close whereas the MDWD stock price gains by 10.82% in the pre-market trading session. MediWound is a pharmaceutical business that develops, produces, and sells innovative, cost-effective tissue repair and regeneration products. MDWD’s approach is based on their enzymatic technology platform, which is dedicated to developing next-generation bioactive treatments for burn, wound, and tissue healing.
>> 7 Top Picks for the Post-Pandemic Economy <<
Recent Past Development
MediWound announced that the enrollment objective for an intermediate evaluation of MediWound’s EscharEx U.S. phase 2 adaptive design trial for the cure of venous leg ulcers (VLUs) has been met, with interim assessment scheduled by the end of July 2021. The purpose of the pre-determined intermediate evaluation is to conduct a futility analysis and perhaps alter the sample size. This research, which aims to enroll 120 patients by the end of 2021, will evaluate the safety and effectiveness of EscharEx to a gel vehicle (placebo control) and non-surgical standard-of-care.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
MediWound is also undertaking a phase 2 open-label, single arm trial to investigate the pharmacological effects of EscharEx in roughly 15 patients with both DFUs and VLUs as part of MDWD’s larger EscharEx development program. The goal of this study is to learn more about what happens in the wound bed during and after EscharEx debridement, as well as to analyze its impact on biofilm load, inflammation decrease, and wound healing initiation. The results of this study are expected in the second half of 2021, according to MediWound.
Sharon Malka, Chief Executive Officer of MediWound stated,
MDWD is thrilled to have reached this significant clinical milestone, and they’re looking forward to the interim evaluation next month. EscharEx has the potential to improve on the existing quality of care and have a substantial influence on chronic wound treatment, as there is an obvious unmet clinical need for a non-surgical fast and effective debridement agent in the outpatient environment. With an annual addressable market of over a billion dollars, EscharEx provides a substantial market potential for MediWound.
